New hope for teens with painful skin condition: sonelokimab trial launches
NCT ID NCT06768671
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 39 times
Summary
This study tests a drug called sonelokimab in 35 teens aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. The goal is to see how the drug moves through the body and if it is safe. Participants receive injections over 24 weeks, and doctors monitor side effects and signs of improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
North Little Rock, Arkansas, 72117, United States
-
Clinical Site
Stanford, California, 94304, United States
-
Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Clinical Site
Hollywood, Florida, 33201, United States
-
Clinical Site
Miami, Florida, 33136, United States
-
Clinical Site
Macon, Georgia, 31217, United States
-
Clinical Site
Sandy Springs, Georgia, 30328, United States
-
Clinical Site
Chicago, Illinois, 60611, United States
-
Clinical Site
Columbus, Indiana, 47201, United States
-
Clinical Site
Murray, Kentucky, 42071, United States
-
Clinical Site
Waterford, Michigan, 48328, United States
-
Clinical Site
Fargo, North Dakota, 58103, United States
-
Clinical Site
Charleston, South Carolina, 29425, United States
-
Clinical Site
Dallas, Texas, 75246, United States
-
Clinical Site
Dallas, Texas, 75390-8575, United States
-
Clinical Site
San Antonio, Texas, 78218, United States
-
Clinical Site
Norfolk, Virginia, 23502, United States
-
Clinical Site
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.